table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID 19 outpatients
bamlanivimab monotherapy OPTIMISE-C19 ... BLAZE-1 phase 2 ...

2 studies excluded by filtering options 1

6920 Rainwater-Lovett, 2021 0130selection pending
6921 Bariola, 2021 1130not a RCTrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons